Extended Therapeutic Hypothermia Fails to Improve Outcomes Post-Cardiac Arrest

Extended durations of therapeutic hypothermia following out-of-hospital cardiac arrest (OHCA) did not demonstrate superior neuroprotection compared to shorter cooling periods, according to findings from the ICECAP randomized trial. The trial aimed to investigate whether prolonging therapeutic hypothermia beyond the standard 24-hour protocol could yield better neurological outcomes and survival rates for patients who experience cardiac arrest outside of a hospital setting. The study enrolled 390 patients across 24 sites in Australia and New Zealand, with participants randomized to receive therapeutic hypothermia for either 24 hours or 72 hours. All patients were cooled to a target temperature of 32°C (89.6°F) for the initial 24-hour period, followed by rewarming. The primary outcome measured was the proportion of patients with a favorable neurological outcome at 6 months, assessed using the Cerebral Performance Category (CPC) scale, where a score of 1 or 2 indicates a favorable outcome. Secondary outcomes included all-cause mortality at 6 months and the incidence of adverse events. The results indicated no significant difference between the 24-hour and 72-hour hypothermia groups in terms of favorable neurological outcomes. Specifically, 75.4% of patients in the 24-hour group achieved a favorable outcome, compared to 73.8% in the 72-hour group. This difference was not statistically significant. Furthermore, the 6-month mortality rates were also comparable between the two arms of the study, with 25.6% mortality in the shorter cooling group and 27.2% in the longer cooling group. The study also reported on the safety profile of the extended hypothermia. While the incidence of certain adverse events, such as arrhythmias during rewarming, was slightly higher in the 72-hour group, these differences were not statistically significant and did not appear to impact overall patient safety or outcomes. The ICECAP trial's findings contribute to a growing body of evidence that suggests current guidelines for therapeutic hypothermia duration, typically 24 hours, are likely sufficient for most OHCA survivors. Previous research, including the Targeted Temperature Management (TTM) trial, had already established the efficacy of maintaining a target temperature of 33°C or 36°C for 24 hours. The ICECAP trial sought to build upon this by exploring whether a more prolonged cooling period could offer additional benefits, particularly in preventing secondary brain injury. The trial's methodology involved rigorous patient selection criteria, including successful resuscitation and return of spontaneous circulation (ROSC), and standardized cooling protocols. The investigators acknowledged that while the trial was adequately powered to detect a clinically meaningful difference, the observed non-significant trends warrant further consideration. However, based on the current data, the added duration of therapeutic hypothermia beyond 24 hours does not appear to provide incremental benefits for neuroprotection or survival in patients following OHCA, and it may potentially increase the risk of certain complications without a clear advantage. The findings are expected to reinforce current clinical practice guidelines and inform future research directions in post-cardiac arrest care.